NEW YORK, April 14, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, notifies investors of class action against Horizon Pharma plc ("Horizon" or "the Company") (NASDAQ: HZNP). The class action has been filed on behalf of a class consisting of all persons or entities who purchased Horizon securities between March 13, 2014 and February 26, 2016, both dates inclusive (the "Class Period").
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act").
The complaint alleges that Defendants violated federal securities laws by making false statements regarding and/or failing to disclose that: (1) Horizon's Prescriptions Made Easy ("PME") program was devised to artificially increase the prices of minor differentiation standard retail drugs; (2) sales revenues from drugs sold through Horizon Pharma's PME program were unsustainable at these overestimated price levels; (3) Horizon Pharma's use of its PME program left Horizon Pharma subject to increased regulatory risks, and (4) as a result, Horizon Pharma's financial statements were materially false and misleading at all relevant times. Once true information entered the market, investors suffered damages.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action, visit the firm's website: http://www.bgandg.com/#!hznp/ygzdg. To discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Horizon you have until May 9, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert---bronstein-gewirtz--grossman-llc-notifies-investors-of-class-action-against-horizon-pharma-plc-hznp-and-lead-plaintiff-deadline-may-9-2016-300251706.html
SOURCE Bronstein, Gewirtz & Grossman, LLC